NCT02743390View on ClinicalTrials.gov

Effects of the TNF-alpha Inhibiton on Hemodynamic Parameters in Resistant Hypertension

PHASE4CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

March 31, 2015

Primary Completion Date

July 31, 2017

Study Completion Date

July 31, 2017

Conditions
Hypertension
Interventions
BIOLOGICAL

Infliximab

Monoclonal antibody biologic drug that inhibits tumour necrosis factor alpha (TNF-α), 3 mg/kg for 2 hours (250mL)

OTHER

Saline

Saline for 2 hours (250mL)

Trial Locations (1)

13083970

University of Campinas (UNICAMP), Campinas

All Listed Sponsors
lead

University of Campinas, Brazil

OTHER

NCT02743390 - Effects of the TNF-alpha Inhibiton on Hemodynamic Parameters in Resistant Hypertension | Biotech Hunter | Biotech Hunter